Skip to main content
Chapter 04 · Dieting Around Peptides

Nutrition around GH peptides

Why food timing matters here when it barely does elsewhere

For most of nutrition, meal timing is a rounding error next to total calories and protein. Growth-hormone peptides are the exception, because the thing they do — provoke a pulse of growth hormone from the pituitary — is directly suppressed by what's in your blood when you dose. Understanding that one piece of physiology is the whole chapter.

The physiology is solid: insulin and fat blunt the pulse

This part is established endocrinology, not forum lore. Growth-hormone release is held in check by somatostatin, and somatostatin tone rises with insulin and glucose. So a carbohydrate load near your dose raises insulin, raises somatostatin, and blunts the GH pulse the peptide is trying to create. A large load of free fatty acids from a heavy fatty meal does the same. GHRH and ghrelin-receptor peptides (tesamorelin, CJC-1295, ipamorelin) work partly by leaning against somatostatin — and feeding into that same brake works against them. The mechanism is real.

The timing guidance is reasoned, not proven — label it honestly

From that physiology, practitioners derive a timing rule: dose in a low-insulin window — commonly no carbohydrate (and minimal protein, which is mildly insulinogenic) for roughly two hours before and 30–60 minutes after a dose, often timed pre-bed to ride the natural nocturnal GH surge, or fasted on waking. Be straight about the evidence here: no controlled trial has validated those specific windows for ipamorelin or CJC-1295, and the FDA-approved GHRH analog tesamorelin was studied without a fasted-window protocol. So the mechanism (insulin and FFAs blunt GH) is solid; the specific clock (2 hours / 30–60 minutes) is sensible extrapolation from that mechanism, not a number a study handed us. Use it as a reasonable default, not gospel.

The carbohydrate tradeoff — cut versus gain

This creates a genuine tension. Carbohydrate raises insulin (bad for the immediate pulse) but also supports IGF-1, recovery, and training performance (good for the result). How you resolve it depends on the phase:

The metabolic marker you must watch

Growth hormone antagonizes insulin, so GH-class protocols predictably drift fasting glucose and insulin upward. This is expected, but it is the cost side of the ledger and it has to be monitored: track HOMA-IR and HbA1c, not just glucose, and don't stack a GH protocol onto an already insulin-resistant metabolism without addressing that first. The nutrition response is to place carbohydrate around training where insulin sensitivity is highest, keep total carbohydrate sane, and let the bloodwork — covered in the Bloodwork Interpretation course — tell you whether the protocol is helping or quietly worsening your glucose handling.

Educational only; not medical or dosing advice. GH-secretagogue timing guidance is practitioner practice derived from GH physiology, not from controlled trials.

← Previous
Dieting on GLP1 agonists
Next →
Recomposition and cutting

Research use only · Not medical advice · The practitioner corpus speaks in mechanisms, not prescriptions